Sildenafil (Generic) Complete Drug-Drug Interaction Profile

How Sildenafil Works: The PDE5-cGMP Pathway

Sildenafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in corpus cavernosum smooth muscle [1]. Sexual stimulation triggers nitric oxide (NO) release from cavernosal nerve terminals, activating guanylate cyclase to produce cGMP. With PDE5 blocked, cGMP accumulates, smooth muscle relaxes, and arterial inflow to the penis increases.

This mechanism explains why every drug interaction profile for sildenafil revolves around two pharmacological axes: anything that increases cGMP through alternative pathways (nitrates, riociguat) creates dangerous additive vasodilation, and anything that slows sildenafil's hepatic clearance through CYP3A4 inhibition amplifies both duration and magnitude of PDE5 blockade. The landmark Goldstein et al. trial (N=532) confirmed efficacy at 25, 50, and 100 mg doses, with adverse events tracking plasma concentration in a dose-dependent manner [1]. Understanding this concentration-effect relationship is the foundation for predicting interaction severity.

Absolute Contraindication: Organic Nitrates

The combination of sildenafil with any nitrate formulation is contraindicated without exception. Nitrates generate NO enzymatically, raising cGMP through guanylate cyclase activation. Sildenafil prevents that cGMP from being broken down. The result is uncontrolled vasodilation.

A controlled hemodynamic study in 16 men demonstrated that sildenafil 100 mg combined with sublingual nitroglycerin 0.4 mg produced a mean additional systolic BP reduction of 51 mmHg and diastolic BP reduction of 29 mmHg beyond placebo plus nitrate [2]. The nadir occurred at 60-90 minutes post-dose. Case reports of fatal outcomes have been documented in men who took sildenafil and then used nitroglycerin for chest pain within 24 hours.

The 2018 ACC/AHA chest pain guidelines specify that nitrates must not be administered within 24 hours of sildenafil use, and within 48 hours for tadalafil [3]. This 24-hour window reflects sildenafil's elimination half-life of 3-5 hours (approximately 5 half-lives). All nitrate formulations are included: nitroglycerin sublingual, isosorbide mononitrate, isosorbide dinitrate, transdermal nitroglycerin patches, and amyl nitrite ("poppers").

Clinical instruction: if a patient on sildenafil presents with acute coronary syndrome, emergency physicians should use non-nitrate anti-anginals (IV beta-blockers, morphine, heparin) and wait the full 24-hour washout before considering nitrate therapy.

Absolute Contraindication: Riociguat (Adempas)

Riociguat stimulates soluble guanylate cyclase (sGC) directly and also sensitizes it to endogenous NO. Co-administration with any PDE5 inhibitor creates dual amplification of the cGMP cascade. The FDA contraindicated this combination based on pharmacodynamic modeling confirmed in the PATENT-1 trial program for pulmonary arterial hypertension [4].

A healthy-volunteer pharmacodynamic study showed that riociguat 2.5 mg with sildenafil 20 mg (the pulmonary hypertension dose) produced symptomatic hypotension in 4 of 8 subjects. No safe combination dose has been identified. The contraindication is absolute regardless of sildenafil indication (ED or PAH) or dose.

CYP3A4 Inhibitors: The Primary Pharmacokinetic Risk

Sildenafil undergoes extensive first-pass hepatic metabolism, predominantly through CYP3A4 with a minor contribution from CYP2C9 [5]. Its active metabolite, N-desmethyl sildenafil, retains approximately 50% of PDE5 inhibitory potency and is itself cleared by CYP3A4. Any drug that inhibits CYP3A4 will raise both parent compound and active metabolite concentrations.

Strong CYP3A4 Inhibitors

Ritonavir represents the most dramatic interaction. A single-dose pharmacokinetic study showed that ritonavir 500 mg BID at steady state increased sildenafil Cmax by 300% and AUC by 1,100% [6]. The FDA labeling recommends a maximum sildenafil dose of 25 mg in 48 hours when co-administered with ritonavir. This applies to all ritonavir-boosted protease inhibitor regimens (lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir).

Ketoconazole 400 mg daily increased sildenafil AUC by 340% and Cmax by 160% in a crossover study of 12 healthy males [5]. The recommended maximum dose is 25 mg. Itraconazole produces similar magnitude effects. Voriconazole and posaconazole should be assumed equivalent until specific PK data indicate otherwise.

Clarithromycin and telithromycin are strong CYP3A4 inhibitors. While no dedicated sildenafil interaction study exists for clarithromycin, its effect on midazolam (a CYP3A4 probe substrate) predicts a 2-4 fold increase in sildenafil exposure. A 25 mg starting dose is appropriate.

Moderate CYP3A4 Inhibitors

Erythromycin 500 mg TID increased sildenafil AUC by 182% and Cmax by 160% [5]. The FDA recommends considering a 25 mg starting dose. Diltiazem and verapamil fall into this category as well, and the combination adds pharmacodynamic blood pressure lowering on top of pharmacokinetic potentiation.

Fluconazole at 200-400 mg daily acts as a moderate CYP3A4 inhibitor and moderate CYP2C9 inhibitor, hitting both sildenafil metabolic pathways simultaneously. Dose reduction to 25 mg is prudent.

Grapefruit juice inhibits intestinal CYP3A4 and increases sildenafil Cmax by approximately 30% with standard consumption (200 mL) [7]. This magnitude is unlikely to be clinically dangerous in isolation, but it stacks with other moderate inhibitors.

Weak CYP3A4 Inhibitors

Cimetidine 800 mg increased sildenafil AUC by 56% [5]. This is a subclinical magnitude for most patients at standard ED doses but becomes relevant when stacked with renal impairment (which independently raises sildenafil AUC by 100%).

CYP3A4 Inducers: Reduced Efficacy

Strong CYP3A4 inducers accelerate sildenafil metabolism, potentially reducing efficacy below therapeutic thresholds.

Rifampin 600 mg daily reduced sildenafil AUC by 86% and Cmax by 74% in a pharmacokinetic interaction study [8]. Patients on rifampin may experience complete treatment failure at standard doses. Carbamazepine, phenytoin, phenobarbital, and efavirenz produce similar induction effects. St. John's Wort (Hypericum perforatum) is a moderate-to-strong inducer that patients may not disclose without direct questioning.

Clinical approach: if a CYP3A4 inducer cannot be discontinued, consider switching to a PDE5 inhibitor less dependent on CYP3A4 metabolism. Avanafil and tadalafil have greater CYP3A4 dependence than sildenafil. Dose escalation of sildenafil to 100 mg may partially compensate for mild-to-moderate induction, but with strong inducers like rifampin, even maximum doses may be subtherapeutic.

Alpha-Adrenergic Blockers: Orthostatic Hypotension Risk

Both sildenafil and alpha-1 blockers reduce peripheral vascular resistance. The FDA-mandated interaction studies demonstrated clinically significant additive hypotension, particularly in the standing position [9].

Doxazosin 4 mg at steady state combined with sildenafil 25 mg produced a mean additional standing SBP reduction of 7.0 mmHg, with individual subjects experiencing drops exceeding 25 mmHg. At sildenafil 100 mg, the mean additional reduction reached 9.5 mmHg, with 58% of subjects experiencing symptomatic hypotension (SBP <85 mmHg or drop >30 mmHg upon standing).

Tamsulosin 0.4 mg (an alpha-1A selective blocker used for BPH) combined with sildenafil 100 mg produced a mean additional standing SBP reduction of 3.5 mmHg [9]. The lower magnitude reflects tamsulosin's selectivity for prostatic alpha-1A receptors over vascular alpha-1B receptors.

Management protocol:

• Patients stable on alpha-blockers should start sildenafil at 25 mg
• Separate administration by at least 4 hours
• Tamsulosin is the preferred alpha-blocker for concurrent sildenafil use
• Avoid sildenafil within 4 hours of alfuzosin, doxazosin, prazosin, or terazosin

Antihypertensive Combinations: Additive Blood Pressure Effects

Sildenafil alone at 100 mg produces a mean 8-10 mmHg reduction in SBP and 5-6 mmHg reduction in DBP, peaking at 1-2 hours post-dose [1]. These reductions are additive with antihypertensive agents.

Amlodipine 5 mg plus sildenafil 100 mg produced a mean additional SBP reduction of 8 mmHg in a crossover study [10]. Most patients tolerated this combination without symptoms, but patients on multiple antihypertensives with baseline SBP <120 mmHg face higher symptomatic risk.

"Patients taking multiple antihypertensives are at increased risk of hemodynamically significant interactions with PDE5 inhibitors, particularly when three or more agents are combined," states the 2018 AUA guideline on erectile dysfunction [11].

ACE inhibitors and ARBs produce modest additive effects (2-4 mmHg additional SBP lowering) that are rarely symptomatic. Thiazide diuretics carry theoretical volume-depletion risk that amplifies postural effects. Beta-blockers minimally interact hemodynamically but some (carvedilol, labetalol) have alpha-blocking properties that add to the orthostatic risk.

Alcohol: A Common But Underappreciated Interaction

Ethanol is both a vasodilator and a CYP2E1 inducer. Acute alcohol intake with sildenafil amplifies the vasodilatory drop. In a controlled study, sildenafil 50 mg combined with 0.5 g/kg ethanol produced mean standing SBP reductions 4-5 mmHg greater than sildenafil alone, with increased reports of dizziness and headache [5].

Beyond hemodynamics, alcohol impairs erectile function through central nervous system depression, partially negating sildenafil's peripheral benefit. "We recommend limiting alcohol to one to two standard drinks when using PDE5 inhibitors," per AUA clinical guidance [11].

Anticoagulants and Antiplatelet Agents

Sildenafil demonstrates mild antiplatelet activity through cGMP-mediated inhibition of platelet activation. The clinical significance is debated but measurable.

A study in 9 healthy volunteers showed that sildenafil 100 mg potentiated the antiplatelet effect of sodium nitroprusside and inhibited collagen-induced platelet aggregation by 43% ex vivo [12]. The interaction with aspirin or clopidogrel is additive on platelet function but has not been associated with increased bleeding risk in large observational cohorts.

Warfarin has no pharmacokinetic interaction with sildenafil (no shared CYP pathways in the clinically relevant direction). INR does not change with sildenafil co-administration. Apixaban and rivarexaban are CYP3A4 substrates and theoretically compete for metabolism, but at therapeutic sildenafil concentrations, this displacement is not clinically significant.

HIV Protease Inhibitors: Special Population Considerations

The HIV-positive population frequently requires sildenafil (ED prevalence exceeds 60% in men with HIV on antiretroviral therapy). Every boosted protease inhibitor regimen raises sildenafil levels dramatically.

| Antiretroviral | Sildenafil AUC Change | Max Dose Recommendation | |---|---|---| | Ritonavir 500 mg BID | +1,100% | 25 mg per 48 hours | | Saquinavir 1200 mg TID | +210% | 25 mg per 24 hours | | Indinavir 800 mg TID | +340% (estimated) | 25 mg per 24 hours | | Cobicistat-boosted regimens | +200-400% (estimated) | 25 mg per 24 hours |

"For patients on ritonavir-boosted protease inhibitors, sildenafil should not exceed 25 mg in a 48-hour period. Start with 25 mg and assess tolerability before re-dosing," per the FDA-approved labeling [6].

Hepatic and Renal Impairment as Interaction Amplifiers

Impaired clearance functions as a "silent interaction" by raising baseline sildenafil levels before any drug-drug interaction even begins.

Hepatic cirrhosis (Child-Pugh A and B): sildenafil AUC increased by 84% and Cmax by 47% due to reduced first-pass metabolism and decreased CYP3A4 enzyme mass [5]. The recommended starting dose is 25 mg. If a CYP3A4 inhibitor is added on top of hepatic impairment, the compound effect on AUC can exceed 400%.

Severe renal impairment (CrCl <30 mL/min): sildenafil AUC increased by 100% [5]. Again, start at 25 mg and apply additional caution if concomitant CYP3A4 inhibitors are present.

The interaction between organ impairment and concomitant inhibitor drugs is multiplicative, not additive. A patient with Child-Pugh B cirrhosis taking erythromycin could have an effective sildenafil exposure 5-7 fold above what a healthy volunteer achieves with the same nominal dose.

Pulmonary Hypertension-Specific Interactions

Sildenafil at 20 mg TID (Revatio) carries the same interaction profile as the ED formulation but with different clinical stakes. These patients often co-administer:

Bosentan (a moderate CYP3A4 inducer) reduces sildenafil AUC by 63% while sildenafil increases bosentan levels by 50% [13]. This bidirectional interaction requires monitoring but is considered manageable in clinical practice. The COMPASS-2 trial evaluated the combination and did not find excess adverse events at the reduced sildenafil exposure.

Epoprostenol (IV prostacyclin) combined with sildenafil 80 mg TID showed additive pulmonary vasodilation without significant systemic hypotension in the PACES trial (N=267) [14]. This is an intentional therapeutic combination, not an adverse interaction.

Ambrisentan has no CYP-mediated interaction with sildenafil. The AMBITION trial used the tadalafil-ambrisentan combination, but the principle applies equally to sildenafil plus ambrisentan.

Food Effects on Drug Interactions

A high-fat meal delays sildenafil Tmax by approximately 60 minutes and reduces Cmax by 29% without significantly affecting AUC [5]. This delay matters for interaction timing. If a patient takes sildenafil with a heavy meal and also takes a moderate CYP3A4 inhibitor, the delayed but prolonged absorption may create a longer-than-expected drug level plateau.

Practical Interaction Management Algorithm

1. Screen the medication list for absolute contraindications (nitrates, riociguat). If present, sildenafil cannot be prescribed.
2. Identify CYP3A4 inhibitors. If strong (ritonavir, ketoconazole, itraconazole, clarithromycin): maximum 25 mg per 48 hours. If moderate (erythromycin, diltiazem, verapamil, fluconazole): start 25 mg, maximum 50 mg.
3. Identify alpha-blockers. If present: start 25 mg, separate by 4+ hours, prefer tamsulosin.
4. Count antihypertensives. Three or more agents with baseline SBP <130: start 25 mg with seated blood pressure monitoring.
5. Assess hepatic/renal function. If Child-Pugh A/B or CrCl <30: start 25 mg and halve the interaction-adjusted maximum dose.
6. Document the interaction assessment in the chart with the final dose rationale.